Last checked at 
(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stock index e-mini futures rose on Monday after closingdown the previous week, as investors focused on the bright spotsin China's factory activity data and ahead of a string ofdomestic economic data. Dow Jones industrial average futures were up 0.37 percent at 18,075, S&P 500 futures were up 0.27 percent at 2,111.75 and Nasdaq 100 futures were up 0.48 percent at 4,532.5.
** ALTERA CORP, Friday close $48.85, +6.08 pctpremarket
** INTEL CORP, Friday close $34.46, -0.61 pctpremarket
Intel agreed to buy Altera for $16.7 billion as the world'sbiggest chipmaker seeks to make up for slowing demand from thePC industry by expanding its line-up of higher-margin chips usedin data centers. The offer of $54 per share in cash is a 10.5percent premium to Altera's Friday close.
** ONCOTHYREON INC, Friday close $3.42, +25.15 pctpremarket
** VBL THERAPEUTICS, Friday close $8.05, +9.94 pctpremarket
** EXELIXIS INC, Friday close $3.15, +11.75 pctpremarket
** IMMUNOGEN INC, Friday close $8.98, +25.39 pctpremarket
** IMMUNOMEDICS INC, Friday close $3.86, +6.22 pctpremarket
The cancer drug makers presented data at the AmericanSociety of Clinical Oncology.
** CTI BIOPHARMA CORP, Friday close $1.94, +5.67pct premarket
The drug developer said patients given its blood cancer drugshowed improvement in key disease symptoms compared with thosegiven a standard of care in a late-stage study.
** ATYR PHARMA INC, Friday close $22.89, +4.19 pctpremarket
BMO started coverage of the drugmaker's stock with an"outperform" rating and a price target of $42, while JP Morganstarted with an "overweight" rating and a $44 price target.
** ALPHA NATURAL RESOURCES INC, Friday close$0.4971, +14.67 pct premarket
** CLOUD PEAK ENERGY INC, Friday close $5.77, -5.20pct premarket
** ARCH COAL INC, Friday close $0.49
Goldman Sachs upgraded Alpha Natural to "neutral" from"sell", saying concerns hurting the coal miner has alreadyreflected on its stock. The brokerage assumed coverage of ArchCoal with "neutral" and cut its rating on Cloud Peak to "sell"from "neutral".
** MOLYCORP INC, Friday close $0.5301, -18.88 pctpremarket
The rare earth miner is expected to announce on Monday thatit would skip a $32.5 million loan payment, which might resultin bankruptcy filing before the end of June, the Wall StreetJournal reported.
** OM GROUP INC, Friday close $26.54, +27.88 pctpremarket
Private equity firm Apollo Global Management LLC will buy the industrial magnet and battery maker for about $1.03billion, or $34 per share - a premium of 28 percent to itsFriday close.
** CELLDEX THERAPEUTICS INC, Friday close$28.87, -2.15 pct premarket
Adding an experimental Celldex Therapeutics vaccine thatenlists the immune system to fight cancer to standard therapyhelped patients with the deadliest type of brain cancer livelonger, according to data from a mid-stage trial presented onSunday.
** GENERAL ELECTRIC CO, Friday close $27.27, +0.00pct premarket
The U.S. conglomerate has launched the sales process for aroughly $40 billion portion of its U.S. commercial lendingassets as a part of its broad retreat from its financebusinesses, sources familiar with the situation said on Sunday.
** COCA-COLA CO, Friday close $40.96
BMO raised the world's largest beverage maker's stock to"outperform" from "market perform" and price target to $48 from$44.
** PFIZER INC, Friday close $34.75
A Phase III trial of the drugmaker's Ibrance showed that, incombination with hormone therapy, the drug more than doubled theduration of disease control for women with the most common typeof breast cancer.
** PRANA BIOTECHNOLOGY LTD, Friday close$1.37, +18.25 pct premarket
The European Commission granted the Australian company'sHuntington's disease treatment "orphan" drug status, which givethe drug 10-year market exclusivity and funded research grantsamong other benefits.
** CELLADON CORP, Friday close $2.31, +16.01 pctpremarket
The troubled drug developer said it was seeking anacquisition or a partnership after its heart drug failed in keymid-stage trial. The company also replaced its CEO with its CFO.
** MICROSOFT CORP, Friday close $46.86
The software company said on Monday its new Windows 10operating system would be available worldwide on July 29 as afree upgrade for users of the most recent versions of Windows.
** JOHNSON & JOHNSON, Friday close $100.14
An experimental biotech drug being developed by the companymay offer hope to multiple myeloma patients who have run out ofoptions, according to data from a mid-stage study released at acancer meeting on Saturday.
** STIFEL FINANCIAL CORP, Friday close $53.26, +0.98pct premarket
The investment bank is in advanced talks to acquire BarclaysPlc's U.S wealth management unit, according to threepeople familiar with the situation.
** NVIDIA CORP, Friday close $22.13
The chipmaker said it expected cloud computing revenue tohit $1 billion in the next two to three years as demand for bigdata analysis drives growth in graphics chips.
** CYPRESS SEMICONDUCTOR CORP, Friday close $13.73
** INTEGRATED SILICON SOLUTION INC, Friday close$20.52
Cypress raised its offer to buy ISSI to $20.25 per share,beating Uphill Investment Co's increased offer. ISSI said itwould hold talks with Cypress.
** WALT DISNEY CO, Friday close $110.37
The media company and theme park operator's shares couldclimb 50 percent over the next three years on its uncannyability to generate profits from its businesses includingmovies, merchandise and parks and cruise lines, Barron's said inits latest edition published on Sunday.
** BRISTOL-MYERS SQUIBB, Friday close $64.6, +2.32pct premarket
The company said the U.S. FDA accepted a marketingapplication for a combination of its cancer drugs Opdivo andYervoy to treat melanoma as a first-line treatment. (Compiled by Abhirup Roy in Bengaluru; Editing by Kirti Pandey)
